Welcome to our lab!

The research in our laboratory is focused on the molecular pathways regulated by the serine/threonine kinase, glycogen synthase kinase-3 (GSK-3), and their implications in pathological disorders. In recent years GSK-3 is emerged as a drug discovery target involved in diabetes, neurodegenerative and affective disorders, including Alzheimer’s disease (AD), Parkinson’s disease, and bipolar disorder. Our aim is to identify mechanisms linking hyperactivity of GSK-3 with these pathologies.

Our laboratory employ multidisciplinary research platforms to address frontier challenges in disease mechanisms and potential solutions. We use molecular and cellular biology, in vitro assays, animal models, and computational tools.

In The Press:

  • Brainnovations graduates first class of neurotech startups – read more
  • ISERD winner (Seventh Framework Programme) – read more
  • New TAU Formulierung kann Parkinson, Alzheimer und Huntington (German language) – read more
  • Invited Speaker -Exploiting substrate recognition for selective inhibition of protein kinases; GSK-3 as an example (7th International Conference: Inhibitors of Protein Kinases, 2012) – read more
  • “Bird Brains” Are Smart on Alzheimer’s (18.4.2011) – read more
  • Nervous System Drug-by-design: Formulation May Slow Parkinson’s, Alzheimer’s, Huntington’s (28.10.2009) – read more
  • A Nervous System Drug-by-Design (26.10.2009) – read more
  • Glycogen synthase kinase-3– a promising therapeutic target: interview with Hagit EldarFinkelman (21.3.2006) – read more
  • Glycogen synthase kinase 3 inhibitors: Proof of concept (8.11.2002) – read more

Wish to join us?

  • Open Positions for Post-doctoral Fellows: For a new grant-supported project in drug development and its implications in neurodegenerative diseases.We are looking for highly motivated individuals for a challenging project that combines basic and industry-oriented research.
  • We are currently seeking for highly motivated Ph.D and M.Sc students.
    For a new and innovative project in drug discovery and drug development: Implications in neurodegenerative disorders.

Please contact us at:
phone: +972-3-6405307
email: heldar@post.tau.ac.il